OB/GYN Clinical Trials

The purpose of this research study is to find out whether pessary or vaginal progesterone lowers the risk of babies being born preterm to women with a short cervix. A pessary is a round, soft silicone device that goes around the cervix. Progesterone is a hormone naturally produced by the placenta.

• Pregnant with twins.
• Gestational age between 16 weeks and 24 weeks.
• Cervical length less than 30 mm

If you decide to participate in this research study, you and your babies may not directly benefit. If the study shows that treatment is successful, you and your babies may benefit if you are assigned to receive the progesterone medication or a pessary. Your participation can potentially benefit mothers and their babies in the future.

This study will evaluate the safety and benefits of treating mild chronic hypertension (CHTN) or high blood pressure, during pregnancy. We are conducting this study to find out whether treating pregnant women with mild CHTN with blood pressure medicines to lower their blood pressure below 140/90 is safe and beneficial for the mother and baby.

• Less than 18 weeks pregnant.
• Pregnant with one baby.
• Have high blood pressures(s).

If you decide to participate in this research study, you and your baby may not directly benefit. Your participation may help doctors determine if it is medically beneficial to treat mild CHTN during pregnancy for both mom and baby in the future.

The nuMoM2b cohort provides an opportunity to evaluate the association between adverse pregnancy outcomes and maternal health later in life. The study is looking at links between pregnancy experiences, heart health, and related conditions. This includes looking at factors related to heart and blood vessel diseases, stroke, lung diseases, sleep problems, diabetes, and kidney disease. It also includes experiences during the nuMoM2b pregnancy and later pregnancies. This is a follow-up study to the nuMoM2b Study. We will be contacting nuMoM2b study participants to see if they are interested in participating.

• You participated in the nuMoM2b study and you agreed to be contacted in the future.

• This study capitalizes on the rich and unique data already collected in nuMoM2b Study. The information collected will contribute significantly to our understanding of how pregnancy outcomes are linked to future health.
• By participating in this study it may help identify risk factors for heart disease in women, develop early detection methods for heart disease risk in women and delay or prevent heart disease in women.

• Pregnant women ages 18 years of age or older having your first baby.
  No previous pregnancies beyond 20 weeks gestation.
• Singleton gestation.
• Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days.

• Participation may help doctors determine the best time to plan for deliveries in the future.
• Participants will receive a modest compensation to reimburse them for time required to participate.

• Singleton pregnancy.
• Positive HCV antibody screen.
• Gestational age at screening no later than 23 weeks and 6 days and gestational age at enrollment no later than 27 weeks and 6 days.

• Participation may help doctors in the future find better treatments for mothers and babies.
  Participants will receive a modest compensation to reimburse them for time required to participate.

• Diagnosis of primary maternal CMV infection.
• Singleton pregnancy.
• Gestational age at enrollment no later than 23 weeks 6 days.